Alteration of Splicing Pattern on Angiotensin Converting Enzyme Gene Due To The Insertion of Alu elements

Dian Laila Purwaningroom1 Purwaningroom, Mohammad Saifurrohman, Nashi Widodo, Jayarani Fatimah Putri, Mifetika Lukitasari

Abstract


Angiotensin Converting Enzyme (ACE) is a zinc metallopeptidase that has a significant role in blood pressure regulation and the pathophysiology of hypertension. ACE has two protein domains, the N-domain and the C-domain, which each has a single active site that functions independently of each other. There is insertion/deletion by 288 bp Alu elements in the intron 16 of ACE gene. The Alu elements potentially alter splicing process. The effect of the insertion of Alu elements in the splicing pattern of the ACE gene has not been reported. Here, we report on the results of splicing pattern analysis of the ACE gene due to the insertion of Alu elements. Using an in-silico approach, we found the presence of Alu elements insertion in intron 16 of ACE caused alternative splicing and experienced exonization. Further analysis showed that the exonization lead to a premature termination codon (PTC), which is raised protein shortening and lost one of its two protein domains. The loss of one protein domain may affect the catalytic activity of ACE. These findings suggest that the Alu elements I/D polymorphism is related to the differences in the catalytic activity of ACE that may influence blood pressure regulation and hypertension.


Full Text:

PDF

References


H. Gavras, “Pathogenesis of hypertension; a review,” J. Med. Sci., vol. 2, no. 1, pp. 25–28, 2009.

S. Vikrant and S. Tiwari, “Essential Hypertension – Pathogenesis and Pathophysiology,” Indian Acad. Clin. Med., vol. 2, pp. 140–161, 2001.

Sharma JN and Al-Banoon, “The Role of Inflammatory Mediator Bradykinin in Cardiovascular and Renal Diseases,” Open Access Sci. Reports, vol. 1, no. 2, pp. 1–7, 2012.

T. Niu, X. Chen, and X. Xu, “Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.,” Drugs, vol. 62, no. 7, pp. 977–993, 2002.

M. Jeong Joong Kim PhD, Hyun-Ju Kim, Hun taeg Chung MD. PhD, Il-Kwon Lee PhD, Jae Hoon Lee, “Okt 12 2012 (Kim et al., 2004) ACE AGT.pdf.” pp. 297–302, 2004.

F. a. Sayed-Tabatabaei, B. a. Oostra, a. Isaacs, C. M. Van Duijn, and J. C. M. Witteman, “ACE polymorphisms,” Circ. Res., vol. 98, pp. 1123–1133, 2006.

R. G. Koyama, R. M. R. P. S. Castro, M. T. De Mello, S. Tufik, and M. Pedrazzoli, “Simple detection of large InDeLS by DHPLC: The ACE gene as a model,” J. Biomed. Biotechnol., vol. 2008, 2008.

M. E. Moreau, N. Garbacki, G. Molinaro, N. J. Brown, F. Marceau, and A. Adam, “The kallikrein-kinin system: current and future pharmacological targets.,” J. Pharmacol. Sci., vol. 99, pp. 6–38, 2005.

H. Lei, I. N. M. Day, and I. Vořechovský, “Exonization of AluYa5 in the human ACE gene requires mutations in both 3′ and 5′ splice sites and is facilitated by a conserved splicing enhancer,” Nucleic Acids Res., vol. 33, no. 12, pp. 3897–3906, 2005.

L. Cartegni, J. Wang, Z. Zhu, M. Q. Zhang, and A. R. Krainer, “ESEfinder: A web resource to identify exonic splicing enhancers,” Nucleic Acids Res., vol. 31, no. 13, pp. 3568–3571, 2003.

J. Ackelman, “Alternative splicing and its regulation under normal and abnormal conditions,” 2010.

S. Fuchs, H. D. Xiao, J. M. Cole, J. W. Adams, K. Frenzel, A. Michaud, H. Zhao, G. Keshelava, M. R. Capecchi, P. Corvol, and K. E. Bernstein, “Role of the N-terminal Catalytic Domain of Angiotensin-converting Enzyme Investigated by Targeted Inactivation in Mice,” J. Biol. Chem., vol. 279, pp. 15946–15953, 2004.

B. Agerholm-Larsen, B. G. Nordestgaard, and a Tybjaerg-Hansen, “ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites.,” Arterioscler. Thromb. Vasc. Biol., vol. 20, no. I, pp. 484–492, 2000.

F. O. Desmet, D. Hamroun, M. Lalande, G. Collod-Bëroud, M. Claustres, and C. Béroud, “Human Splicing Finder: An online bioinformatics tool to predict splicing signals,” Nucleic Acids Res., vol. 37, pp. 1–14, 2009.

L. a Chasin, “Searching for splicing motifs.,” Adv. Exp. Med. Biol., vol. 623, no. Cv, pp. 85–106, 2007.

J. Yang, R. Yan, A. Roy, D. Xu, J. Poisson, and Y. Zhang, “correspondEnce The I-TASSER Suite : protein structure and function prediction a,” Nat. Publ. Gr., vol. 12, no. 1, pp. 7–8, 2015.

A. Roy, A. Kucukural, and Y. Zhang, “I-TASSER: a unified platform for automated protein structure and function prediction.,” Nat. Protoc., vol. 5, no. 4, pp. 725–738, 2010.

Y. Zhang, “I-TASSER server for protein 3D structure prediction.,” BMC Bioinformatics, vol. 9, p. 40, 2008.

G. Lev-Maor, R. Sorek, N. Shomron, and G. Ast, “The birth of an alternatively spliced exon: 3’ splice-site selection in Alu exons.,” Science, vol. 300, no. May, pp. 1288–1291, 2003.

R. Sorek, G. Ast, and D. Graur, “Alu-containing exons are alternatively spliced,” Genome Res., vol. 12, pp. 1060–1067, 2002.

and M. H. E. Oliver Smithies, Hyung-Suk Kim, Nobuyuki Takahashi, “Importance of quantitative genetic variations in the etiology of hypertension.” pp. 2265–2280, 2000.

S. Mukae, S. Itoh, S. Aoki, T. Iwata, K. Nishio, R. Sato, and T. Katagiri, “Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough.,” J. Hum. Hypertens., vol. 16, pp. 857–863, 2002.

Y. F. Li, X. M. Zhu, F. Liu, C. S. Xiao, Y. F. Bian, H. Li, J. Cai, R. S. Li, and X. C. Yang, “Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACE inhibitor-related cough: A meta-analysis,” PLoS One, vol. 7, no. 6, 2012.

A. Salami and I. Katibi, “Angiotensin converting Enzyme Inhibitors associated cough a prospective evaluation in hypertensives.,” Ann. Afr. Med., vol. 4, no. 3, pp. 118–121, 2005.